Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer

<p>Supplementary Figure S6. Distribution of HER2 gene ratio in relation to PIK3CA mutation status and HER2-enriched subtype.</p>

Saved in:

書目詳細資料
主要作者:	Jamunarani Veeraraghavan (16461809) (author)
其他作者:	Carolina Gutierrez (14958125) (author), Carmine De Angelis (16461812) (author), Robert Davis (16461815) (author), Tao Wang (14952136) (author), Tomas Pascual (16461818) (author), Pier Selenica (15052857) (author), Katherine Sanchez (16461821) (author), Hiroaki Nitta (16461824) (author), Monesh Kapadia (16461827) (author), Anne C. Pavlick (16461830) (author), Patricia Galvan (16461833) (author), Brent Rexer (16461836) (author), Andres Forero-Torres (15053759) (author), Rita Nanda (15034401) (author), Anna M. Storniolo (16461839) (author), Ian E. Krop (15029231) (author), Matthew P. Goetz (8863130) (author), Julie R. Nangia (15123189) (author), Antonio C. Wolff (15017274) (author), Britta Weigelt (15051465) (author), Jorge S. Reis-Filho (15052878) (author), Susan G. Hilsenbeck (14952139) (author), Aleix Prat (14950504) (author), C. Kent Osborne (15055636) (author), Rachel Schiff (14958948) (author), Mothaffar F. Rimawi (15055651) (author)
出版:	2025
主題:	Cancer Cancer Detection and Diagnosis Biomarkers Prognostic biomarkers Breast Cancer
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
由: Jamunarani Veeraraghavan (16461809)
出版: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
由: Jamunarani Veeraraghavan (16461809)
出版: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
由: Jamunarani Veeraraghavan (16461809)
出版: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
由: Jamunarani Veeraraghavan (16461809)
出版: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
由: Jamunarani Veeraraghavan (16461809)
出版: (2025)

Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
由: Jamunarani Veeraraghavan (16461809)
出版: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
由: Nigel Bundred (15046233)
出版: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
由: Nigel Bundred (15046233)
出版: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
由: Nigel Bundred (15046233)
出版: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
由: Nigel Bundred (15046233)
出版: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
由: Nigel Bundred (15046233)
出版: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
由: Emil Christensen (15054394)
出版: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
由: Emil Christensen (15054394)
出版: (2025)

Supplementary Tables S1-5 from METTL3-Mediated m<sup>6</sup>A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
由: Yiming Wu (15306005)
出版: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
由: Hansol Lee (15054787)
出版: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
由: Hansol Lee (15054787)
出版: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
由: Hansol Lee (15054787)
出版: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
由: Hansol Lee (15054787)
出版: (2025)

Supplementary Video S1 from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
由: Xiaojiang Duan (15439264)
出版: (2025)

Supplementary Video S2A from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
由: Xiaojiang Duan (15439264)
出版: (2025)

Supplementary Video S2B from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
由: Xiaojiang Duan (15439264)
出版: (2025)

Supplementary Video S2C from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
由: Xiaojiang Duan (15439264)
出版: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
由: Milana A. Bergamino (15038015)
出版: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
由: Milana A. Bergamino (15038015)
出版: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
由: Milana A. Bergamino (15038015)
出版: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
由: Milana A. Bergamino (15038015)
出版: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
由: Milana A. Bergamino (15038015)
出版: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
由: Milana A. Bergamino (15038015)
出版: (2025)

Supplementary Data from Genetic Modulation of <i>BET1L</i> Confers Colorectal Cancer Susceptibility by Reducing miRNA Binding and m<sup>6</sup>A Modification
由: Shuwei Li (16437116)
出版: (2025)

Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
由: Hiroshi Kagamu (14961732)
出版: (2025)

Supplementary Appendix S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
由: Bouchra Tawk (15389486)
出版: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
由: Ankita Mitra (17141783)
出版: (2025)

Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
由: Ankita Mitra (17141783)
出版: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
由: Ankita Mitra (17141783)
出版: (2025)

UMAP visualizations of extracted CD8<sup> + </sup> T and CD4<sup> + </sup> T cell barcodes, employed for downstream subsequent single-cell trajectory and classification analyses.
由: Fatemeh Keikha (20917848)
出版: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
由: Carlotta Antoniotti (15352506)
出版: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
由: Carlotta Antoniotti (15352506)
出版: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
由: Carlotta Antoniotti (15352506)
出版: (2025)

Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
由: Javier Pascual (15018176)
出版: (2025)

Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
由: Javier Pascual (15018176)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_o2kn1dvnrj61bv2hkst5nkc1dm